Capecitabine in the management of colorectal cancer

References

• JemalASiegelRXuJWardECancer statistics, 2010CA Cancer J Clin201060527730020610543
   PubMed Web of Science ®Google Scholar
• JohnstonPGKayeSCapecitabine: a novel agent for the treatment of solid tumorsAnticancer Drugs200112863964611604550
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkThe NCCN Clinical Practice Guidelines in Oncology: Colon Cancer (Version 2.2011) Available from: http://www.nccn.org/professionals/physician_gls/recently_updated.asp. Accessed November 29, 2010.
   Google Scholar
• National Comprehensive Cancer NetworkThe NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer (Version 2.2011) Available from: http://www.nccn.org/professionals/physician_gls/recently_updated.asp. Accessed November 29, 2010.
   Google Scholar
• TanakaMYoshidaSSaneyoshiMYamaguchiTUtilization of 5-fluoro-2′-deoxyuridine triphosphate and 5-fluoro-2′-deoxycytidine triphosphate in DNA synthesis by DNA polymerases alpha and beta from calf thymusCancer Res19814110413241357285016
   PubMed Web of Science ®Google Scholar
• MatsuokaHUeoHSugimachiKAkiyoshiTPreliminary evidence that incorporation of 5-fluorouracil into RNA correlates with antitumor responseCancer Invest19921042652691628225
   PubMed Web of Science ®Google Scholar
• MiwaMUraMNishidaMDesign of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissueEur J Cancer1998348127412819849491
   PubMed Web of Science ®Google Scholar
• SchüllerJCassidyJDumontEPreferential activation of capecitabine in tumor following oral administration to colorectal cancer patientsCancer Chemother Pharmacol200045429129710755317
   PubMed Web of Science ®Google Scholar
• SawadaNIshikawaTFukaseYNishidaMYoshikuboTIshitsukaHInduction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenograftsClin Cancer Res199844101310199563897
   PubMed Web of Science ®Google Scholar
• EndoMShinboriNFukaseYInduction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5′-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor modelsInt J Cancer199983112713410449619
   PubMed Web of Science ®Google Scholar
• MoritaTTokueABiomodulation of 5-fluorouracil by interferon-alpha in human renal carcinoma cells: relationship to the expression of thymidine phosphorylaseCancer Chemother Pharmacol1999442919610412941
   PubMed Web of Science ®Google Scholar
• SawadaNIshikawaTSekiguchiFTanakaYIshitsukaHX-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenograftsClin Cancer Res19995102948295310537364
   PubMed Web of Science ®Google Scholar
• ReignerBBleschKWeidekammEClinical pharmacokinetics of capecitabineClin Pharmacokinet20014028510411286326
   PubMed Web of Science ®Google Scholar
• MackeanMPlantingATwelvesCPhase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancerJ Clin Oncol1998169297729859738566
   PubMed Web of Science ®Google Scholar
• ReignerBWatanabeTSchüllerJPharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancerCancer Chemother Pharmacol200352319320112783206
   PubMed Web of Science ®Google Scholar
• JudsonIRBealePJTrigoJMA human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drugInvest New Drugs1999171495610555122
   PubMed Web of Science ®Google Scholar
• ReignerBVerweijJDirixLEffect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patientsClin Cancer Res1998449419489563888
   PubMed Web of Science ®Google Scholar
• HallerDGCassidyJClarkeSJPotential regional differences for the tolerability profiles of fluoropyrimidinesJ Clin Oncol200826132118212318445840
   PubMed Web of Science ®Google Scholar
• HochsterHSHartLLRamanathanRKSafety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE StudyJ Clin Oncol200826213523352918640933
   PubMed Web of Science ®Google Scholar
• MidgleyRKerrDJCapecitabine: have we got the dose right?Nat Clin Pract Oncol200961172418936793
   PubMedGoogle Scholar
• TwelvesCWongANowackiMPCapecitabine as adjuvant treatment for stage III colon cancerN Engl J Med2005352262696270415987918
   PubMed Web of Science ®Google Scholar
• HallerDGCassidyJTaberneroJEfficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (NO16968): no impact of age on disease-free survival (DFS) [abstract 284]Proceedings of the Gastrointestinal Cancers Symposium2010 Oct 1–3Washington, DC, USA
   Google Scholar
• Roche Investor Update 2010. Roche provides results on Avastin in adjuvant colon cancer. Available from: http://www.roche.com/investors/ir_update/inv-update-2010-09-18b.htm. Accessed November 29, 2010.
   Google Scholar
• Glynne-JonesRDunstJSebag-MontefioreDThe integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been?Ann Oncol200617336137116500912
   PubMed Web of Science ®Google Scholar
• National Cancer Institute Clinical Trials Phase III randomized study of adjuvant chemotherapy comprising capecitabine and oxaliplatin versus standard follow-up care in patients with clear margins after complete resection of locally advanced rectal cancer. Available from: http://www.cancer.gov/clinicaltrials/CRUK-CHRONICLE. Accessed November 29, 2010.
   Google Scholar
• SauerRBeckerHHohenbergerWGerman Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancerN Engl J Med2004351171731174015496622
   PubMed Web of Science ®Google Scholar
• De PaoliAChiaraSLuppiGCapecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II studyAnn Oncol200617224625116282246
   PubMed Web of Science ®Google Scholar
• KrishnanSJanjanNASkibberJMPhase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancerInt J Radiat Oncol Biol Phys200666376277117011451
   PubMed Web of Science ®Google Scholar
• KimJSKimJSChoMJSongKSYoonWHPreoperative chemoradiation using oral capecitabine in locally advanced rectal cancerInt J Radiat Oncol Biol Phys200254240340812243814
   PubMed Web of Science ®Google Scholar
• KimJCKimTWKimJHPreoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancerInt J Radiat Oncol Biol Phys200563234635315913913
   PubMed Web of Science ®Google Scholar
• HofheinzRWenzFPostSCapecitabine (Cape) versus 5-fluorouracil (5-FU)-based (neo-)adjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): safety results of a randomized, phase III trial [abstract 4014]J Clin Oncol20092715S401419620480
   PubMed Web of Science ®Google Scholar
• RödelCLierschTHermannRMMulticenter phase II trial of chemoradiation with oxaliplatin for rectal cancerJ Clin Oncol200725111011717194912
   PubMed Web of Science ®Google Scholar
• ChuaYJBarbachanoYCunninghamDNeoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trialLancet Oncol201011324124820106720
   PubMed Web of Science ®Google Scholar
• GérardJPAzriaDGourgou-BourgadeSComparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2J Clin Oncol201028101638164420194850
   PubMed Web of Science ®Google Scholar
• MachielsJPDuckLHonhonBPhase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape studyAnn Oncol200516121898190516219623
   PubMed Web of Science ®Google Scholar
• RödelCGrabenbauerGGPapadopoulosTHohenbergerWSchmollHJSauerRPhase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancerJ Clin Oncol200321163098310412915600
   PubMed Web of Science ®Google Scholar
• WillekeFHorisbergerKKraus-TiefenbacherUA phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancerBr J Cancer200796691291717325705
   PubMed Web of Science ®Google Scholar
• KlautkeGKüchenmeisterUFoitzikTConcurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I/II studyBr J Cancer200694797698116552435
   PubMed Web of Science ®Google Scholar
• MachielsJPSempouxCScallietPPhase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancerAnn Oncol200718473874417208931
   PubMed Web of Science ®Google Scholar
• RödelCArnoldDHippMPhase I–II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancerInt J Radiat Oncol Biol Phys20087041081108617881150
   PubMed Web of Science ®Google Scholar
• TwelvesCGollinsSGrieveRSamuelLA randomised crossover trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancerAnn Oncol200617223924516344278
   PubMed Web of Science ®Google Scholar
• LiuGFranssenEFitchMIWarnerEPatient preferences for oral versus intravenous palliative chemotherapyJ Clin Oncol19971511101158996131
   PubMed Web of Science ®Google Scholar
• LingWFanJMaYMaYWangHCapecitabine-based chemotherapy for metastatic colorectal cancerJ Cancer Res Clin Oncol201010.1007/s00432-010-0954-0
   Web of Science ®Google Scholar
• HoffPMAnsariRBatistGComparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III studyJ Clin Oncol20011982282229211304782
   PubMed Web of Science ®Google Scholar
• Van CutsemETwelvesCCassidyJXeloda Colorectal Cancer Study Group. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III studyJ Clin Oncol200119214097410611689577
   PubMed Web of Science ®Google Scholar
• CassidyJClarkeSDíaz-RubioERandomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancerJ Clin Oncol200826122006201218421053
   PubMed Web of Science ®Google Scholar
• PorschenRArkenauHTKubickaSAIO Colorectal Study GroupPhase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study GroupJ Clin Oncol200725274217422317548840
   PubMed Web of Science ®Google Scholar
• Díaz-RubioETaberneroJGómez-EspañaASpanish Cooperative Group for the Treatment of Digestive Tumors TrialPhase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors TrialJ Clin Oncol200725274224423017548839
   PubMed Web of Science ®Google Scholar
• DucreuxMBennounaJHebbarMEfficacy and safety findings from a randomized phase III study of capecitabine (X) + oxaliplatin (O) (XELOX) vs infusional 5-FU/LV + O (FOLFOX-6) for metastatic colorectal cancer (MCRC) [abstract 4029]J Clin Oncol20072518S4029
   Google Scholar
• RothenbergMLCoxJVButtsCCapecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority studyAnn Oncol200819101720172618550577
   PubMed Web of Science ®Google Scholar
• KoopmanMAntoniniNFDoumaJSequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trialLancet2007370958213514217630036
   PubMed Web of Science ®Google Scholar
• FuchsCSMarshallJMitchellERandomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C studyJ Clin Oncol200725304779478617947725
   PubMed Web of Science ®Google Scholar
• KöhneCHDe GreveJHartmannJTIrinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015Ann Oncol200819592092618065406
   PubMed Web of Science ®Google Scholar
• WalkoCMLindleyCCapecitabine: a reviewClin Ther2005271234415763604
   PubMed Web of Science ®Google Scholar
• Díaz-RubioEBurrisHDouillardJYThe X-Act Study GroupSafety of capecitabine (X) compared to fluorouracil/leucovorin (5-FU/LV) for the adjuvant treatment of elderly colon cancer patients (pts) [abstract 3737]J Clin Oncol20042214S3737
   Google Scholar
• FeliuJEscuderoPLlosaFCapecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group studyJ Clin Oncol200523133104311115860870
   PubMed Web of Science ®Google Scholar
• FeliuJSafontMJSaludACapecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancerBr J Cancer2010102101468147320424611
   PubMed Web of Science ®Google Scholar
• RosatiGCordioSBordonaroRCapecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II studyAnn Oncol201021478178619713248
   PubMed Web of Science ®Google Scholar
• HennigIMNaikJDBrownSSevere sequence-specific toxicity when capecitabine is given after fluorouracil and leucovorinJ Clin Oncol200826203411341718612156
   PubMed Web of Science ®Google Scholar
• ChuESchulmanKLZeltSSongXCosts associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancerCancer200911571412142319195048
   PubMed Web of Science ®Google Scholar
• CassidyJDouillardJYTwelvesCPharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes’ C colon cancer: the X-ACT trialBr J Cancer20069481122112916622438
   PubMed Web of Science ®Google Scholar
• ShiroiwaTFukudaTTsutaniKCost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trialsBr J Cancer20091011121819491895
   PubMed Web of Science ®Google Scholar
• ChuESchulmanKLMcKennaEFJrCartwrightTPatients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparisonClin Colorectal Cancer20109422923720920995
   PubMed Web of Science ®Google Scholar
• VelenikVOcvirkJOmejcMNeoadjuvant bevacizumab, capecitabine, and radiotherapy in locally advanced rectal cancer: interim results of a phase II CRAB trial [abstract e14006]J Clin Oncol20102815e14006
   Web of Science ®Google Scholar